Surrozen Stock Earnings Estimates Increased by HC Wainwright

Surrozen, Inc. (NASDAQ:SRZN) – Equities researchers at HC Wainwright raised their FY2030 earnings estimates for Surrozen in a report released on Friday, September 25th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($4.34) for the year, up from their previous forecast of ($5.53). HC Wainwright has a “Buy” rating and a $54.00 price objective on the stock. The consensus estimate for Surrozen’s current full-year earnings is ($1.01) per share.

A number of other equities analysts have also recently weighed in on the stock. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. William Blair assumed coverage on Surrozen in a research note on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $48.33.

Surrozen Price Performance

Surrozen stock opened at $31.98 on Tuesday. Surrozen has a 12-month low of $11.39 and a 12-month high of $37.83. The company has a market capitalization of $371.29 million, a price-to-earnings ratio of -0.79 and a beta of 0.56. The firm’s fifty day moving average price is $22.22 and its 200 day moving average price is $24.94.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.88. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $0.47 million.

Insider Buying and Selling

In other Surrozen news, major shareholder Tcg Crossover Gp Ii, Llc sold 325,000 shares of the firm’s stock in a transaction on Wednesday, July 22nd. The shares were sold at an average price of $21.25, for a total transaction of $6,906,250.00. Following the completion of the transaction, the insider directly owned 574,047 shares of the company’s stock, valued at $12,198,498.75. This trade represents a 36.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 31.74% of the stock is owned by company insiders.

Institutional Investors Weigh In On Surrozen

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp acquired a new position in Surrozen in the second quarter worth about $399,000. Perceptive Advisors LLC acquired a new stake in Surrozen during the first quarter valued at approximately $6,682,000. ADAR1 Capital Management LLC acquired a new stake in Surrozen during the first quarter valued at approximately $350,000. Renaissance Technologies LLC lifted its holdings in Surrozen by 117.1% during the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after buying an additional 26,500 shares during the last quarter. Finally, Eversept Partners LP lifted its holdings in Surrozen by 23.8% during the 4th quarter. Eversept Partners LP now owns 95,286 shares of the company’s stock worth $2,153,000 after buying an additional 18,289 shares during the last quarter. Institutional investors and hedge funds own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biotechnology company developing regenerative medicines designed to activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen’s approach is intended to stimulate the pathway selectively in specific tissues while limiting unwanted effects elsewhere in the body.

The company’s product candidates are based on engineered antibody therapeutics and its proprietary SWEETS platform. Surrozen has focused its research on potential treatments for diseases affecting the liver, gastrointestinal system and eyes, where impaired tissue repair or abnormal signaling may contribute to disease progression.